Key result
SGLT-2 inhibitors were associated with a significantly lower reporting rate of atrial fibrillation compared to other glucose-lowering medications (4.8 vs 8.7 per 1000 reports; PRR 0.55).
Why the study?
SGLT2i reduce heart failure risk and new data indicate they can prevent AF, prompting evaluation of the association between SGLT2i and AF in real-world adverse event reports.
Population
62,098 adverse event reports for SGLT2i and 642,031 reports for other ATC10 drugs in FAERS
Comparison
SGLT-2 i vs other glucose lowering medications (ATC10 class)
Design
Pharmacovigilance database study of FAERS
Authors
Loading...
Supports lower AF reporting with SGLT2 inhibitors in pharmacovigilance data; leaves open confirmation in prospective trials.
Observational (n=704,129)
Effect estimate: PRR 0.55 (95% CI 0.49-0.62)
Absolute Event Rate: 4.8% vs 8.7%
p-value: p=<0.001
Bonora et al. (2021) conducted an observational in Adverse events in patients taking glucose-lowering medications (n=704,129). SGLT-2 inhibitors vs. Other glucose-lowering medications (ATC A10 class) was evaluated on Reporting of atrial fibrillation (AF) (PRR 0.55, 95% CI 0.49-0.62, p=<0.001). SGLT-2 inhibitors were associated with a significantly lower reporting rate of atrial fibrillation compared to other glucose-lowering medications (4.8 vs 8.7 per 1000 reports; PRR 0.55).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: